Evaluation of concurrent chemoradiotherapy for locally advanced NSCLC according to EGFR mutation status

• DOI: 10.3892/ol.2017.6231
• Publication Date: 2017-05-23T09:31:08Z
• Authors: Mikiko Ishihara; Satoshi Igawa; Jiichiro Sasaki; Sakiko Otani; Tomoya Fukui; Shinichiro Ryuge; Ken Katono; Yasuhiro Hiyoshi; Masashi Kasajima; Hisashi Mitsufuji; Masaru Kubota; Masanori Yokoba; Masato Katagiri; Akane Sekiguchi; Itaru Soda; Hiromichi Ishiyama; Kazushige Hayakawa; Noriyuki Masuda
• Keywords: Chemoradiotherapy; Wild type

Concurrent chemoradiotherapy (cCRT) is the standard treatment for patients with locally advanced non-small cell lung cancer (LA-NSCLC). However, efficacy and safety of this has not been compared between who possess epidermal growth factor receptor (EGFR) mutations wild-type EGFR. The objective present study was to evaluate effect presence EGFR gene in LA-NSCLC receiving cCRT. Between January 2007 December 2013, records 64 were reviewed retrospectively. data statistically analyzed cCRT according mutation status. In total, 15/64 revealed mutations, 23%, comprised mutant group. progression-free survival time significantly shorter group patient tumors exhibiting EGFR, 6.3 9.5 months, respectively (P<0.001). overall rate longer group, although difference significant, 37.1 21.1 (P=0.26). disease recurred all whilst recurrence 89%. frequency distant metastasis higher conclusion, these suggest that additional studies are required identify strategies reinforcing cCRT, a focus on potential use tyrosine kinase inhibitors an mutation.